如何降低肺癌术后复发风险是学界探索多年的老大难问题。此前，CheckMate-816 以全球首个国际多中心 III 期临床肺癌新辅助免疫治疗研究的姿态荣登新英格兰医学杂志，成为可切除非小细胞肺癌的重要治疗手段之一。 2023 欧洲肿瘤内科学会（ESMO）上，来自美国 MD ...

近日，在「2025 年肺癌年终盘点暨第 3 届临床热词发布会」上，CheckMate-816 研究荣膺肺癌「10 大临床热词」及「年度关注研究」双项榜首，再度引发广泛关注。 作为全球首个在可切除非小细胞肺癌（NSCLC）中证实新辅助免疫联合化疗可带来显著总生存（OS ...

SAN FRANCISCO--(BUSINESS WIRE)--Checkmate, a personalized smart shopping tool that makes it easy for users to discover brands, apply savings and manage their orders post-purchase, today announced it ...

In the era of immunotherapy breakthroughs, the results of the CheckMate 067 trial crown PD-1 inhibitors as the new standard of care for patients with metastatic melanoma, a disease with a very dismal ...

Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently ...